Search for
Large bone tumours with amputation of limbs Complex Biopsy
Biopsy
Report in 288Hrs
At Home
No Fasting Required
Details
Biopsy from amputated specimen.
₹1,110₹1,586
30% OFF
Large Bone Tumours with Amputation of Limbs Complex Biopsy
- Why is it done?
- Definitive histopathological diagnosis of large bone malignancies following surgical amputation or limb salvage procedures involving tumor resection
- Determination of tumor type, grade, and biological behavior to guide treatment planning and prognostic assessment
- Assessment of surgical margins to evaluate adequacy of tumor resection and risk of local recurrence
- Identification of specific molecular and genetic alterations for targeted therapy selection and prognostic stratification
- Evaluation of necrotic response following neoadjuvant chemotherapy (percent tumor necrosis)
- Detection of metastatic disease and assessment of soft tissue involvement
- Performed following amputation or wide surgical excision of primary bone tumors (typically osteosarcoma, Ewing sarcoma, chondrosarcoma, or other high-grade malignancies)
- Normal Range
- Normal Result (Negative): Absence of malignant cellular features; normal bone and soft tissue architecture; clear surgical margins (>1 cm from tumor edge); no evidence of necrosis, hemorrhage, or abnormal proliferation
- Abnormal Result (Positive): Presence of malignant cells with specific morphologic features; confirmed diagnosis of primary or metastatic malignancy; close or positive surgical margins (<1 cm or at margin); extensive necrosis or tumor infiltration
- Grading Systems Used: Salzer-Kuntschik Grading (0-5 scale for necrosis); Enneking Staging; Broders Grading; WHO classification for bone tumors; TNM staging where applicable
- Tumor Necrosis Response: >90% necrosis indicates excellent chemotherapy response; 50-90% indicates good response; <50% indicates poor response
- Interpretation
- Histologic Diagnosis: Specific tumor type identified (osteosarcoma, chondrosarcoma, Ewing sarcoma, etc.) determines prognosis, chemotherapy sensitivity, and long-term survival rates; confirmation guides adjuvant therapy decisions
- Tumor Grade: Low-grade (Grade 1) tumors: slower growth, better prognosis; High-grade (Grade 3-4) tumors: aggressive behavior, higher metastatic potential, requires intensive multimodal therapy
- Surgical Margins: Negative margins (>1 cm clearance) indicate adequate resection with low recurrence risk; positive margins suggest residual disease risk requiring additional therapy or re-resection; close margins may warrant adjuvant radiation consideration
- Chemotherapy Response: >90% tumor necrosis predicts superior survival outcomes; 50-90% represents intermediate response; <50% poor response requires treatment modification; percent necrosis is independent prognostic factor
- Molecular Findings: Specific translocations (EWSR1-FLI1 in Ewing sarcoma) confirm diagnosis; p53, MAPK pathway mutations affect prognosis; HER2 status guides targeted therapy eligibility
- Soft Tissue Extension: Presence of extraosseous tumor component indicates stage T3 disease with poorer prognosis; vascular invasion predicts higher metastatic risk
- Factors Affecting Interpretation: Specimen fixation quality, multiple sampling sites, prior biopsy tract contamination, extent of necrotic material, decalcification effects, processing artifacts
- Associated Organs
- Primary Organ System: Skeletal system (bones of lower extremities primarily, upper extremities, pelvis); muscular system (adjacent skeletal muscle); vascular system (arteries and veins); lymphatic system; nervous system (peripheral nerves)
- Common Malignancies Associated: Osteosarcoma (most common primary malignant bone tumor); Ewing sarcoma; Chondrosarcoma; Fibrosarcoma; Liposarcoma; Rhabdomyosarcoma; Synovial sarcoma; Clear cell sarcoma
- Disease Conditions Diagnosed: High-grade primary bone malignancies; soft tissue sarcomas with bone involvement; metastatic disease to bone; local recurrence; lymph node metastases; secondary malignancies
- Complications Associated with Abnormal Results: Pulmonary metastases (most common site); osseous metastases; regional lymph node involvement; local recurrence at amputation site; visceral metastases; pathologic fractures; infection; compartment syndrome
- Impact on Adjacent Structures: Vascular invasion indicates need for aggressive chemotherapy; neural invasion affects symptom severity and treatment planning; infiltration into joints compromises surgical margins and limb salvage feasibility
- Follow-up Tests
- Molecular and Genetic Testing: Fluorescence in situ hybridization (FISH) for specific translocations; Next-generation sequencing (NGS) for mutation profiling; Gene expression profiling; Immunohistochemistry for prognostic markers (MDM2, Ki-67, p53)
- Imaging Follow-up: Chest CT scan (evaluate for pulmonary metastases); Total body PET-CT or bone scan (detect osseous metastases); MRI of amputation site (assess local recurrence); Regular surveillance imaging every 3-6 months for first 2-3 years
- Laboratory Monitoring: Alkaline phosphatase levels; Lactate dehydrogenase (LDH); Tumor markers specific to tumor type; Circulating tumor DNA (ctDNA) testing; Complete blood count and metabolic panel during chemotherapy
- Additional Pathologic Review: Second opinion from specialized bone/soft tissue pathologist; Reference laboratory confirmation; Expert panel review for complex cases; Comparison with pre-operative diagnostic biopsy
- Lymph Node Assessment: Sentinel lymph node biopsy if indicated; Regional lymph node ultrasound or CT; Histopathologic examination if nodes enlarged or suspicious
- Treatment Planning Based on Results: Adjuvant chemotherapy initiation; Radiation therapy planning; Targeted therapy eligibility assessment; Immunotherapy consideration; Clinical trial enrollment evaluation; Prosthetic limb and rehabilitation planning
- Long-term Surveillance: Every 3 months for years 1-2; Every 6 months for years 2-5; Annually thereafter up to 10 years; Lifetime monitoring for recurrence or secondary malignancies
- Fasting Required?
- Fasting Requirement: NO - Fasting is not required for histopathologic biopsy examination. This is a surgical pathology specimen obtained from tissue resection, not a blood test.
- Pre-operative Patient Preparation: NPO (nothing by mouth) 6-8 hours prior to amputation/resection surgery; Discontinue anticoagulants per surgeon instructions; Continue essential medications unless otherwise directed; Obtain informed consent; Baseline blood work (CBC, CMP, coagulation studies)
- Specimen Collection Requirements: Specimen placed in appropriate fixative (typically 10% formalin) immediately after surgery; Fresh tissue sections obtained for special studies (flow cytometry, molecular testing) if required; Multiple representative samplings from tumor, margins, and adjacent tissue; Proper specimen labeling with patient identifiers and anatomic location
- Associated Lab Work if Needed: Fasting required if blood tests (baseline alkaline phosphatase, LDH) ordered pre-operatively; 8-12 hour fasting recommended for baseline metabolic assessment before adjuvant chemotherapy initiation
- Medications: Continue all routine medications unless instructed otherwise by surgical team; NSAIDs typically held 5-7 days before surgery; Anticoagulants managed per specific protocols; Pain medications as prescribed
- Special Instructions: Patient should discuss specimen handling with pathology team pre-operatively; Ensure consent for molecular/genetic testing if planned; Coordinate with tumor board regarding special studies; Plan for expedited analysis if needed; Psychological support referral recommended post-amputation; Phantom limb pain management discussion with anesthesia
How our test process works!
